1262108-14-4

Basic information

• Product Name: Vistusertib
• Synonyms: Vistusertib
• CAS NO: 1262108-14-4
• Molecular Formula: C₂₇H₂₉F₅O₄S
• Molecular Weight: 544.573776
• Mol File: 1262108-14-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 651.1±55.0 °C(Predicted)
• Appearance: /
• Density: 1.41±0.1 g/cm3(Predicted)
• PKA: 12.13±0.60(Predicted)
• CAS DataBase Reference: Vistusertib(CAS DataBase Reference)
• NIST Chemistry Reference: Vistusertib(1262108-14-4)
• EPA Substance Registry System: Vistusertib(1262108-14-4)

Safety Data

• Hazardous Substances Data: 1262108-14-4(Hazardous Substances Data)

Usage

General Description

Vistusertib, also known as AZD2014, is a potent and selective dual mTORC1 and mTORC2 inhibitor that has shown promising results in preclinical studies and early-phase clinical trials for the treatment of various cancers. It inhibits the activity of the mTOR protein, which plays a crucial role in regulating cell growth and proliferation. By targeting both mTOR complexes, Vistusertib has the potential to disrupt multiple signaling pathways involved in cancer development and progression. Clinical trials have demonstrated its efficacy in combination with other anticancer drugs, and further research is ongoing to evaluate its potential as a targeted therapy for a range of cancer types. Overall, Vistusertib shows promise as a novel treatment option for cancer patients.

Upstream product

• 1262108-06-4 (11β,17β)-20,20,21,21,21-pentafluoro-17-hydroxy-11-[4-(methylsulfanyl)phenyl]-19-norpregna-4,9-dien-3-one 
• 1026668-61-0 (5′R,8′S,10′R,13′S,14′S,17′S)-5,5,13′-trimethyl-17′-(pentafluoroethyl)-1′,2′,7′,8′,12′,13′,14′,15′,16′,17′-decahydro-6′H-spiro[1,3-dioxane-2,3′-[5,10]epoxycyclopenta[a]phenanthren]-17′-ol 
• 91175-93-8 (5′R,8′S,10′R,13′S,14′S)-5,5,13′-trimethyl-1′,2′,6′,7′,8′,12′,13′,14′,15′,16′-decahydro-17′H-spiro[1,3-dioxane-2,3′-[5,10]epoxycyclopenta[a]phenanthren]-17′-one 
• 1262108-37-1 (5R,8S,11R,13S,14S,17S)-5',5',13-trimethyl-11-[4-(methylsulfanyl)phenyl]-17-(pentafluoroethyl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxane]-5,17(4H)-diol 

Relevant articles and documents

SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRM) AND STABILIZED ESTROGEN LEVEL IN PATIENT

The present invention is related to Selective Progesterone Receptor Modulators (SPRM) as described and defined herein, and covers the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of sexual hormone de

17-HYDROXY-17-PENTAFLUOROETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHOD OF PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF DISEASES

The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of Formula I with progesterone antagonizing action and method of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereo